Frontiers in Immunology,
Journal Year:
2022,
Volume and Issue:
13
Published: Oct. 21, 2022
Reactivation
of
tumor
infiltrating
T
lymphocytes
(TILs)
with
immune
checkpoint
inhibitors
or
co-stimulators
has
proven
to
be
an
effective
anti-cancer
strategy
for
a
broad
range
malignancies.
However,
epithelial
ovarian
cancer
(EOC)
remains
largely
refractory
current
cell-targeting
immunotherapeutics.
Therefore,
identification
novel
targets
and
biomarkers
prognostic
value
EOC
is
warranted.
Combining
multicolor
immunofluorescent
staining’s
single
cell
RNA-sequencing
analysis,
we
here
identified
TIM-3/CXCL13-positive
tissue-resident
memory
(CD8/CD103-positive)
(Trm)
population
in
EOC.
Analysis
cohort
~175
patients
high-grade
serous
revealed
TIM-3-positive
Trm
were
significantly
associated
improved
patient
survival.
As
CXCL13-positive
CD8-positive
cells
have
been
strongly
linked
response
anti-PD1
blockade,
combinatorial
TIM-3
PD-1
blockade
therapy
may
interest
the
(re)activation
immunity
The
CXC
chemokine
receptor
5
(CXCR5)
is
a
member
of
the
G
protein-coupled
family
that
highly
expressed
in
B
cells
and
subset
T
such
as
follicular
helper
cells.
Various
types
cancers,
including
non-small
cell
lung
cancer,
breast
prostate
cancer
also
express
CXCR5;
therefore,
antibodies
specifically
bind
to
CXCR5
could
be
useful
for
clarification
mechanisms
progression.
In
this
study,
we
aimed
develop
high-affinity
monoclonal
(mAbs)
flow
cytometry
against
mouse
(mCXCR5).
established
anti-mCXCR5
mAb,
Cx5Mab-3
(rat
IgG2b,
kappa),
reacted
with
mCXCR5-overexpressed
Chinese
hamster
ovary
(CHO)-K1
(CHO/mCXCR5)
by
cytometry.
Kinetic
analyses
using
indicated
dissociation
constants
(KD)
CHO/mCXCR5
7.2
×
10−10
M,
indicating
detecting
mCXCR5
high
affinity.
Advanced Science,
Journal Year:
2024,
Volume and Issue:
unknown
Published: Nov. 7, 2024
B
cells
are
crucial
component
of
humoral
immunity,
and
their
role
in
the
tumor
immune
microenvironment
(TME)
has
garnered
significant
attention
recent
years.
These
hold
great
potential
application
prospects
field
immunotherapy.
Research
demonstrated
that
TME
can
remodel
various
cell
functions,
including
proliferation,
differentiation,
antigen
presentation,
antibody
production,
thereby
invalidating
anti-tumor
effects
cells.
Concurrently,
numerous
checkpoints
(ICs)
on
surface
upregulated.
Aberrant
B-cell
IC
signals
not
only
impair
function
themselves,
but
also
modulate
tumor-killing
other
cells,
ultimately
fostering
an
immunosuppressive
facilitating
escape.
Blocking
ICs
is
beneficial
for
reversing
restoring
responses.
In
this
paper,
intricate
connection
between
delved
into,
emphasizing
critical
targeting
which
may
provide
valuable
insights
future
development
immunotherapy
based
Frontiers in Genetics,
Journal Year:
2022,
Volume and Issue:
13
Published: Sept. 29, 2022
In
the
tumor
microenvironment,
tumor-infiltrating
immune
cells
(TIICs)
are
a
key
component.
Different
types
of
TIICs
play
distinct
roles.
CD8+
T
and
natural
killer
(NK)
could
secrete
soluble
factors
to
hinder
cell
growth,
whereas
regulatory
(Tregs)
myeloid-derived
suppressor
(MDSCs)
release
inhibitory
promote
growth
progression.
meantime,
growing
body
evidence
illustrates
that
balance
between
pro-
anti-tumor
responses
is
associated
with
prognosis
in
microenvironment.
Therefore,
order
boost
response
improve
clinical
outcome
patients,
variety
strategies
for
targeting
based
on
their
respective
functions
have
been
developed
obtained
good
treatment
benefits,
including
mainly
checkpoint
blockade
(ICB),
adoptive
therapies
(ACT),
chimeric
antigen
receptor
(CAR)
cells,
various
monoclonal
antibodies.
recent
years,
tumor-specific
features
further
investigated
by
methods,
such
as
using
single-cell
RNA
sequencing
(scRNA-seq),
results
indicate
these
diverse
phenotypes
different
tumors
emerge
inconsistent
therapeutic
responses.
Hence,
we
concluded
advances
functions,
prognostic
values,
immunotherapy
each
tumors.
Frontiers in Immunology,
Journal Year:
2022,
Volume and Issue:
13
Published: Oct. 21, 2022
Reactivation
of
tumor
infiltrating
T
lymphocytes
(TILs)
with
immune
checkpoint
inhibitors
or
co-stimulators
has
proven
to
be
an
effective
anti-cancer
strategy
for
a
broad
range
malignancies.
However,
epithelial
ovarian
cancer
(EOC)
remains
largely
refractory
current
cell-targeting
immunotherapeutics.
Therefore,
identification
novel
targets
and
biomarkers
prognostic
value
EOC
is
warranted.
Combining
multicolor
immunofluorescent
staining’s
single
cell
RNA-sequencing
analysis,
we
here
identified
TIM-3/CXCL13-positive
tissue-resident
memory
(CD8/CD103-positive)
(Trm)
population
in
EOC.
Analysis
cohort
~175
patients
high-grade
serous
revealed
TIM-3-positive
Trm
were
significantly
associated
improved
patient
survival.
As
CXCL13-positive
CD8-positive
cells
have
been
strongly
linked
response
anti-PD1
blockade,
combinatorial
TIM-3
PD-1
blockade
therapy
may
interest
the
(re)activation
immunity
